Main Article Content
Objective: This study aims to forecast the number of deaths and cases in Turkey 150 days after (6 August 2020) the first occurrence of COVID-19 in Turkey. The data used is from 10 March 2020 (the first day has seen of COVID-19 in Turkey) to 15 June 2020 and includes people of all ages from all provinces of Turkey.
Material and Method: The relationship between cases, deaths, patients in intensive care units, intubated patients, and recovered patients, which are observations of COVID-19, was examined with a correlation matrix. Afterward, the ARIMA (0,2,4) model to forecast the number of COVID-19 cases in Turkey and the ARIMA(0,3,1) model to forecast the number of COVID-19 deaths in Turkey were established.
Result: COVID-19 cases were forecasted that there may be 266.692 cases in Turkey on 6 August in the 1st model. Subsequently, a similar forecast has been made on COVID-19 deaths in Turkey on 6 August in the 2nd model. COVID-19 deaths were forecasted that there may be 5718. The p-values of these parameters of models were observed statistically significant (p<0.05). Later, the stationarity of ARIMA models related to these estimates was examined. According to the Augmented Dickey-Fuller (ADF) test results, ARIMA models were stationary and statistically convenient to use (p<0.05). Finally, the Jarque-Bera (JB) test examining the normal distribution assumption was applied and the models were found to be normally distributed.
Conclusions: Consequently, there is an increase in both predicted cases and predicted deaths by the 150th day of COVID-19. These estimates show that the number of cases and deaths will not decrease to zero level until August 6. Factors such as the biological development of the COVID-19 virus, the rate of spread of COVID-19 disease, or the presence of COVID-19 therapy may not cause any increase in these observations. On the contrary, more than expected increase may occur in observed cases.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
2. Henderson D. Smallpox: the death of a disease. 1st ed. Amherst, NY: Prometheus Book; 2009.
3. Spreeuwenberg P, Kroneman M, Paget J. Reassessing the global mortality burden of the 1918 influenza pandemic. American Journal of Epidemiology. 2018;187(12):2561-7.
4. who.int [Internet]. Geneva: Naming the coronavirus disease (COVID-19) and the virus that causes it; c2020 [cited 2020 Mar 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
5. ictvonline.org [Internet]. Berlin: International Committee on Taxonomy of Viruses (ICTV); c2020 [cited 2020 Mar 31]. Available from: https://talk.ictvonline.org/.
6. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Medical Journal. 2020;133(9):1015-24.
7. Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted 2020. The New England Journal of Medicine. 2020;382(13):1268-9.
8. cdc.gov [Internet]. Atlanta: Centers for Disease Control and Prevention. Symptoms of Coronavirus; c2019 [cited 2020 Mar 31]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
9. who.int [Internet]. Geneva: Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases; c2020 [cited 2020 Mar 31]. Available from: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.
10. Hao Q, Wu H, Wang Q. Difficulties in false negative diagnosis of coronavirus disease 2019: a case report. North Carolina: Research Square; 2020.
11. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK554776/.
12. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30:269-71.
13. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? The Lancet Infectious Diseases. 2003;3(11):722-7.
14. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model. Cell Research. 2013;23(2):300-2.
15. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends Advance Publication. 2020;14(1):72-3.
16. who.int [Internet]. Geneva: WHO R&D blueprint: informal consultation on prioritiza-tion of candidate therapeutic agents for use in novel coronavirus 2019 infection; c2020 [cited 2020 Apr 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-RDBlueprint%28nCoV%29-2020.1-eng.pdf.
17. gisanddata.maps.arcgis.com [Internet]. Maryland: Coronavirus COVID-19 global cases by the center for systems science and engineering (CSSE); c2020 [cited 2020 June 15]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
18. worldometers.info [Internet]. Shanghai: World Population; c2020 [cited 2020 Apr 6]. Available from: https://www.worldometers.info/world-population.
19. saglik.gov.tr [Internet]. Ankara: Republic of Turkey, Ministry of Health; c2020 [cited 2020 June 15]. Available from: https://covid19.saglik.gov.tr/.
20. Horn RA, Johnson CR. Matrix analysis. 1st ed. Cambridge: Cambridge University Press; 1985.
21. Box GEP, Pierce DA. Distribution of residual autocorrelations in autoregressive integrated moving average time series models. Journal of the American Statistical Association. 1970;65(332):1509-26.
22. Ljung GM, Box GEP. On a measure of lack of fit in time series models. Biometrika. 1978; 65(2):297-303.
23. Warriyar KV, Abraham B, Variyath AM. Robustness of some portmanteau correlation tests in financial time series. American Journal of Mathematical and Management Sciences. 2016;35(1):67-76.
24. Bako H, Rusiman M, Ibrahim L, Hazel Monica M.-P. Predictive modeling of pelagic fish catch in malaysia using seasonal ARIMA models. Agriculture, Forestry and Fisheries. 2013;2(3):136-40.
25. Thomopoulos NT. Applied forecasting methods. 1st ed. New Jersey, Englewood Cliffs: Prentice-Hall; 1980.
26. Mushtaq R. Augmented dickey fuller test. SSRN Electronic Journal. 2012;1-19.
27. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. Journal of The American Statistical Association. 1979;74(366):427-31.
28. Dickey DA, Fuller WA. Likelihood ratio statistics for autoregressive time series with a unit root. Econometrica: Journal of the Econometric Society. 1981;49(4):1057-72.
29. Hosseini SM, Ahmad Z, Lai YW. The role of macroeconomic variables on stock market index in china and india. International Journal of Economics and Finance. 2011;3(6):233-43.
30. Jarque CM, Bera AK. Efficient tests for normality, homoscedasticity and serial independence of regression residuals. Economics Letters. 1980;6:255-9.
31. Thadewald T, Büning H. Jarque-bera test and its competitors for testing normality – a power comparison. Journal of Applied Statistics. 2007;34(1):87-105.